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Introduction
The U.S. National Nanotechnology Initiative defines Nanomaterial 
as materials that have at least one dimension in the 1-100 nm 
range. Despite its size, you can see things with the effects of 
nanoparticles all around you. They give the sunset its red color, 
allow birds to navigate, and help geckos stick to trees. All around 
us, there are nano-sized materials present form volcanoes, forest 
fires, viral particles, biogenic magnetite and combustion prod-
ucts (Nano.gov). What has taken the scientific world by storm 
in the last few years is not the naturally existing nanoparticles, 
but rather, it is the newfound ability to create new materials on 
a nanoscale. The term “Nanotechnology” by the material science 
standard refers to the creation of these new particles and its 
usage. In the physical sciences, nanotechnology is associated 
with the quantum behavior of subatomic particles in nanoscale 
structures. In the biomedical sciences, nanotechnology is used 
in imaging, diagnosing, monitoring diseases, gene delivery, artifi-
cial implants, and targeted drug delivery (Nasimi, Haidari 2013). 
Engineered nanomaterials are useful, specifically in drug delivery, 
because of their large surface area to mass ratio (Oberdorster 
2004). When a drug is encapsulated in a nanoparticle, there is 
a more accurate delivery to the targeted tissue. Drug permea-
bility will also increase, thereby reducing the dosing frequency. 
For instance, an intravenously administered hydrophilic drug has 
poor reabsorption after glomerular filtration, often caused by the 
rapid renal clearance of the drug; whereas, encapsulating the drug 
in a nanoparticle reduces renal clearance and allows for better 
absorption. An orally administered drug has to endure enzymatic 
degradation in the gastrointestinal tract and a pass through the 
liver before it enters systemic circulation. By encapsulating the 
drug in a nanoparticle, the exposures to harsh conditions on the 
digestive tract are minimized (Kadam, et al 2012).
The key to using nanoparticles in drug delivery systems is ensur-
ing that the drug can be released at the proper time. In that vein, 
a biodegradable nanoparticle formulation would be needed, as it 
is the intention to transport and release the drug in order to be 
effective. However, model studies to the behavior of nanopar-
ticles have largely been conducted with non-degradable parti-
cles. Most data concerning the biological behavior and toxicity 
of particles comes from studies on inhaled nanoparticles. This is 
part of the unintended release of ultrafine or nanoparticles by 
combustion-derived processes such as diesel exhaust particles 
(Oberdörster, Oberdörster et al 2005). Research has demon-
strated that exposure to these combustion derived ultrafine par-
ticles/nanoparticles is associated with a wide variety of effects, 
including vascular thrombosis, peripheral thrombosis, increased 
plasma fibrinogen levels and cardiovascular effects (Radomski, 
Jurasz et al 2005; Oberdorster, Oberdörster et al 2005). Since 
the size for both ultrafine and nanoparticles (100 nm) is relative-
ly the same, many use both terms as equivalents. Based on the 
similarity of character and size between the two, researchers are 
speculating that the adverse effects of ultrafine particles, as part 
of environmental pollution, may be similar to the negative effects 
of engineered nanoparticles.
Methods
The NCBI PubMedCentral database, the Touro College library 
Database, Proquest, and Google Scholar were search en-
gines used to find information. The following key words were 
searched to obtain research related to this paper: nanotechnol-
ogy, nanoparticles, nano-medicine, nanotechnology and medical 
uses, nanotechnology and drug delivery, toxic effect of nanopar-
ticles, negative effects of engineered nanoparticles, toxicity and 
nanoparticles, applications of nanoparticles, and hazards of nan-
otechnology. Further sources were found by using appropriate 
references cited in various journals and reviews.
Nanoparticles and Drug Delivery
Nanoparticles are formed through natural or human facilitated 
degeneration of larger structures or by controlled assembly 
processes. These procedures occur either in the gas phase, in 
a plasma, in a vacuum phase or in the liquid phase (SCENHIR 
2006). Naturally occurring nanoparticles are found in the air 
in surprisingly high concentrations - approximately 106 to 108 
nanoparticles per liter of air depending on conditions. They orig-
inate from the oxidation of volatile compounds, diesel and car 
engines, and photo-oxidation. The most significant concentration 
of particles and smallest particle size are associated with high-
speed road traffic, apparently due to the subtle conditions during 
concomitant cooling and dilution of the exhaust gases (SCENHIR 
2006). Although there are many naturally occurring nanoparticles, 
the ones that are man-made and biodegradable are the ones that 
are used in drug delivery systems (Oberdorster 2004).
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Preparation of Nanoparticles
Before choosing a method to prepare nanoparticles for use in 
drug delivery, many factors have to be taken into account. Some 
of these factors are the size of the nanoparticle required, the 
inherent properties of the drug (ex. solubility, stability), surface 
characteristics and the degree of biodegradability, biocompati-
bility and toxicity (Mohanraj, Chen 2006). The following are the 
three main methods used to prepare nanoparticles for drug 
delivery:
Dispersion of preformed polymers: A polymer is dissolved in an 
organic solvent, which is also used as the solvent for the hy-
drophobic drug. This mixture is then emulsified in an aqueous 
solution containing a surfactant. After a stable emulsion is formed, 
the organic solvent is evaporated. Some of the polymers used in 
this method include poly- lactic acid, poly(D, L-glycolide), poly(D, 
L-lactide-co-glycolide) and poly(cyanoacrylate) (Mohanraj, Chen 
2006). 
Polymerization method: Monomers a polymerized and form 
nanoparticles in aqueous solution. The drug is encapsulated either 
by dissolving it in the polymerization medium or by absorption 
onto the nanoparticles post- polymerization. The nanoparticles 
are separated from the suspension by ultra-centrifugation (Reis, 
et al 2006).
Coacervation or ionic gelation method: A significant amount of 
research has been focused on the preparation of nanoparticles 
using hydrophilic, biodegradable polymers such as chitosan, gela-
tin and sodium alginate. A method was developed by P. Calvo, et 
al. for preparing hydrophilic chitosan nanoparticles by ionic gela-
tion. They mixed two aqueous solutions together- one was the 
polymer chitosan and the other was the polyanion sodium tri-
phosphate. The positively charged group of the chitosan interacts 
with the negatively charged triphosphate to form coacervates 
(an aggregate of colloidal droplets held together by electrostatic 
attractive forces) with a size in the range of a nanometer (Calvo, 
et al 1997).
Drug Loading and Release
The ideal nanoparticle for drug delivery should have a high 
drug loading capacity, thereby reducing the quantity of matrix 
materials (Mohanraj, Chen 2006). The two main ways to load 
a drug into a nanoparticle is by incorporating it at the time of 
nanoparticle production, or absorbing the drug after formation 
of the nanoparticles by incubating the nanoparticle carrier with 
a concentrated drug solution. The efficiency in loading the drug 
is very much dependent on the solubility of the drug in a solid 
state into the matrix material or polymer. The solubility is related 
to the polymer composition, molecular weight, the drug-polymer 
interactions and the type of functional group present (ester or 
carboxyl) (Govender, et al 1999). Once the drug is loaded, the 
next step is to ensure an opportune release. In general, the re-
lease of the drug is dependent on the solubility of the drug, drug 
diffusion through the nanoparticle matrix and nanoparticle ma-
trix degradation. (Mohanraj, Chen 2006). Very often, the drug is 
released by interactions between intracellular chemicals and the 
nanoparticle matrix. For example, the cationic surface of some 
nanoparticles allows penetration through the cell membrane 
and the drug is then released after the nanoparticle matrix is 
triggered by intracellular glutathione. Another example is the re-
duction of cadmium sulfate or ferric oxide (which are used to cap 
silica nanoparticles) by thiols that release the molecules inside 
the nanoparticle (Nasimi, Haidari 2013). An alternate mechanism 
for release is the use of pH-responsive nanomaterials. A further 
achievement in the area of drug release was reached when a 
method was developed to use multifunctional super-magnetic 
nanoparticles that can be released remotely (Derfus, et al. 2007).
Passing the Blood Brain Barrier (BBB)
From several standpoints the brain is a challenging organ for 
drug delivery. First, the occurrence of progressive diseases in 
the brain will increase with the aging population. Secondly, the 
blood brain barrier (BBB) is well known as the best gatekeeper 
in the body toward exogenous substances. Generally pharma-
ceuticals including most small molecules do not cross the BBB. 
The BBB is formed by tight junctions between the cerebral en-
dothelial cells, which abolish all aqueous diffusion pathways, and 
by biochemical systems consisting of enzymes, which specifically 
metabolize many drugs. However, the barrier properties may be 
compromised intentionally or unintentionally by allowing the 
passage of nanoparticles (Kreuter, et al. 2002). Many studies were 
done that show coating of the nanoparticles with the polysor-
bate (80) surfactants resulted in transport of drugs across the 
blood brain barrier (Schroder  1996). It is interesting to note that 
studies were first done using engineered nanoparticles to cross 
the BBB; however, with increased research it was discovered and 
published that natural ultrafine particles can cross the BBB and 
cause damage. 
Toxicological Hazards of Nanoparticles
General concepts
To effectively tap into the potential of Nanotechnology in 
Nanomedicine, full attention is needed to focus on safety and 
toxicological issues. For pharmaceuticals, precise drug delivery 
formulations may be used to increase the so called “therapeutic 
ratio” which is the margin between the dose needed for clini-
cal efficacy and the dose that would induce adverse side effects 
(toxicity). Also, for these specific formulations, a toxicological 
evaluation is needed. The US Food and Drug Administration ap-
proval is crucial for clinical applications of nanotechnology, but 
considerable problems come into account when it comes to 
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approving nanotechnology-based products. The Food and Drug 
Administration regulate pharmaceuticals and biological devices 
differently, and it is not yet clear how emerging nanotherapeutics 
will be evaluated.  It is important to have a safety guide particu-
larly in the applications of nanoparticles for drug delivery. In these 
applications, particles are brought intentionally into the human 
body and environment (Buxton, et al 2003). Opinions started to 
divert when toxicologists claimed that new science, methods and 
protocols are needed (Nel et al 2006). However, the need for 
a safety guide is now underlined by several expert reports and 
more importantly by the following concepts:
1) Nanomaterials are made for their unique surface properties 
as opposed to the similar properties of bulk materials. Since the 
surface is the layer that interacts with the body tissue, and an 
essential factor of particle response, these unique properties 
need to be investigated from a toxicological perspective. When 
nanoparticles are used for their distinctive reactive characteris-
tics, it may be probable that these same characteristics also have 
an impact on the toxicity of such particles. Although existing 
tests and procedures in drug and device assessment may work 
to detect many risks related to the use of these nanoparticles, 
it cannot be presumed that these assays will detect all potential 
risks. (SCENIHR 2006) The toxicity may differ depending on the 
type of particles used, i.e., biological versus non-biological origin.
2) Nanoparticles are recognized as having different physical and 
chemical characteristics from micron-sized particles. This may 
result in changed body distribution, passage of the blood brain 
barrier and triggering of blood coagulation pathways. In view 
of these characteristics, specific emphasis should be on testing 
and studying the distribution of nanoparticles. What is currently 
lacking is a basic comprehension of the biological behavior of 
nanoparticles in relation to the distribution in vivo both at the 
organ and cellular level.
Using nanoparticles as a drug carrier may reduce the toxicity of 
the incorporated drug. In general, research focuses on the toxici-
ty of the entire formulation. The results of the nanoparticles itself 
are not described, so differentiation between drug and nanopar-
ticle toxicity cannot be made. There should be a specific emphasis 
on the toxicity of the “empty” non-drug loaded particles. This is 
especially important when slow or non-degradable particles are 
used for drug delivery. (Oberdorster, Maynard, et al. 2005)
Evidence for Nanoparticle Toxicity
The largest database on the toxicity of nanoparticles comes from 
the PM10 literature (particulate matter with a size below 10 mm), 
where studies on inhalation and the ‘Nanoparticle hypothesis’ 
have proved to be a powerful drive for research (Oberdörster, 
Oberdörster et al 2005). Therefore it is relevant to discuss this 
Particle type Description
PM10, PM2.5 Particle mass fraction in ambient air with a mean diameter of 10 or 2.5 μm respectively. Basis of current standards for ambient particles in Europe and USA
Coarse particles The mass fraction of PM10, which is bigger than 2.5 μm
Ultrafine particles 
(PM0.1)
The fraction of PM10 with a size cut-off at 0.1 μm. Contains primary particles and 
agglomerates smaller than 100 nm
PSP
Poorly soluble particles with low specific toxicity. Maybe be fine or ultrafine. 
Terminology used in relation to bulk synthetic particles. Examples TiO2, carbon 
blacks, Amorphous silica, Iron oxides (Fe2O3), Zinc oxides (ZnO)
CDNP Combustion derived nanoparticles, such as diesel exhaust particles (DEP)
DEP Diesel exhaust particles
Table 1
Various denominations of particles in inhalation toxicology and drug delivery in relation to their source (ambient, bulk, engineered)
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evidence with the expectation that it will shed light on the tox-
icity of engineered nanoparticles.  The adverse health effects of 
particulate matter (PM) are measurable as causes of respiratory 
disease and deaths as well as hospitalizations and deaths from 
respiratory and cardiovascular disease. Many laboratory studies 
have been done to investigate the effects of ultrafine and PM par-
ticles.  It was found that some nanoparticles might have the extra 
potential of affecting cardiovascular disease directly. Vascular 
function was impaired after inhalation of diesel exhaust particles. 
However, data to date is limited and not all studies of nanoparti-
cles have shown significant translocation from lung to the blood. 
Understanding clearance kinetics of inhaled ambient air nanopar-
ticles will also be important in understanding the potential for 
adverse effects. (Oberdorster, Maynard, et al. 2005)
The current standard in particle toxicology is that ultrafine am-
bient air particles have the potential of affecting cardiovascular 
disease both indirectly via pulmonary inflammation and directly 
through particle distribution. Although significant, this property 
of redistribution has yet to be demonstrated for nanoparticles 
present in real PM10’s. It should be noted that there are several 
mechanisms whereby nanoparticles could lead to inflammatory 
effects, as is the case for larger particles. These mechanisms are 
either based on the large surface area of a particle core or on 
soluble components released by the nanoparticles (Schins, et 
al. 2004).  Several toxicological studies support the argument 
that nanoparticles in PM10’s could drive inflammatory effects. 
There are a number of components of PM10’s that contribute 
to the mass but have little toxicity, including salts such as sul-
fates, chlorides and ammonium salts and nitrates. In fact, within 
PM10’s there are only few components that toxicologists would 
identify as likely causes of adverse effects – i.e., particle surfaces, 
organics, metals and endotoxins. A large surface area, organics 
and metals are all characteristic of combustion–derived particles 
and so these have attracted considerable toxicological attention 
(Donaldson, et al. 2005).
Effects of Nanoparticle Toxicity
Many physicochemical factors can influence the potential biological 
interactions and toxicity of nanoparticles. Therefore, it is import-
ant to consider the extent to which the physicochemical proper-
ties of nanoparticles have been characterized in any given study. 
Without sufficient characterization, it is extremely challenging to 
interpret the results of individual studies and virtually impossible 
to compare the results of different studies, even in cases where 
the same nanoparticle has been investigated. As a result, the ability 
to identify parameters that might influence toxicity is hampered. 
Although there is not yet a universally accepted standard of pa-
rameters that is deemed necessary for nanoparticle characteri-
zation, recent reports have highlighted several key physicochem-
ical elements for which it is strongly recommended that data be 
reported (Oberdörster, Maynard, et al. 2005).  These limitations 
include method of synthesis, size, size distribution, shape, com-
position, crystal structure, aggregation and agglomeration status, 
dissolution, purity, surface area, and other surface characteristics. 
Classification of nanoparticles in the context of the experimental 
contact media (cell culture media, dosing solution, aerosol, etc.) is 
also of substantial importance, as some physicochemical parame-
ters are likely to differ depending on whether they are determined 
in the experimental media or in the bulk (i.e., “as received”) state. 
Unfortunately, the inclusion of all these parameters in publications 
describing nanoparticle toxicity studies appears to be rare. 
Nanoparticles in The Lungs
When nanoparticles enter the respiratory system, they are thought 
to cause damage that results primarily from lung particle overload. 
This is due to the inability of alveolar macrophages to recognize 
and/or clear particles of this size, resulting in a particle build up, 
chronic inflammation, fibrosis, and tumor-genesis. However, many 
studies have not shown a correlation between nanoparticles and 
inflammation (Card, et al, 2008). Many studies also track whether 
the particles translocate from the pulmonary system into sys-
temic circulation. One of the studies reported to date indicate 
that inhaled 99mtechnetium-labeled carbon nanoparticles, which 
are man-made, are not detected outside of the lungs in significant 
quantities after inhalation. However, as mentioned to by Mills et 
al., these findings do not indicate that other nanoparticles will be-
have in the same manner, nor do they rule out the possibility that 
nanoparticles may interact with and influence the vascular system 
in the lungs. Moreover, the studies conducted to date have used a 
single inhalation exposure protocol, and it is possible that repeat-
ed exposures may result in greater pulmonary accumulation and 
transfer of significant quantities of nanoparticles to the circulation 
(Mills, et al. 2006). 
Fibrosis is a condition that many researchers believe is caused by 
nanoparticle exposure. Many experiments were done using animals 
to test the effects of primarily carbon nanotubes, carbon black, 
fullerenes, silica, and metal-based nanoparticles including titanium 
dioxide, silver, and nickel. Though it is known that the pathogenic 
mechanisms underlying animal models of lung fibrosis and human 
lung fibrosis are not necessarily the same, increased collagen de-
posits and structural deviations to the lungs can result in changed 
respiratory mechanics that are common features of both. Fibrosis 
in animal models is defined by increased collagen content and/or 
histopathological evidence of structural alterations to the lung that 
are consistent with fibrosis (Card, et al, 2008). It was found that 
the type of carbon nanotubes, their length, and the way specific 
fibers interact, all have varying effects on pulmonary inflammation 
and fibrosis. Studies have found that the longer the nanotube fiber 
length, the greater the toxicity, and the more likely it is to cause 
fibrosis and cancer (Donaldson, et al. 2006).
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Effects on Blood and Cardiovascular System
In a study by Radomski, et al, (2005) the effects of various 
nanoparticles on platelet function were studied. In vitro studies 
were done using human blood samples, and then in vivo studies 
were done in rats to confirm the effects of platelet- aggrega-
tion found in the human blood. Engineered nanoparticles were 
found to cause activation and aggregation of human platelets. 
The efficacy of the nanoparticles in blood aggregation in vitro 
was matched by the same results in the rats. Treatment with 
nanoparticles caused rat vascular thrombosis. The data shows 
that not all nanomaterials act similar in this test, and that sur-
face area is not the only factor playing a role here. The data also 
validates the idea that mainly cationic species have an effect on 
blood clotting. Interestingly, this was the first study that allows 
bridging of data, since a PM10 sample (SRM1648) was included in 
the test-series, in combination with nanoparticles. The PM sample 
actually showed a lower effect on platelet aggregation compared 
to the carbon nanotubes (Radomski, Jurasz et al 2005). Another 
study shows that repeated exposure to PM10’s causes a systemic 
inflammatory response, including bone marrow stimulation, and 
is related to the progression of atherosclerosis in the coronary 
arteries and aorta (Suwa, et al. 2002).
Uptake and Effects of Nanoparticles in The Brain
Nanoparticles can gain access to the brain by two different 
mechanisms. (1) Trans-synaptic transport after inhalation through 
the olfactory epithelium. (2) Uptake through the blood-brain 
barrier. The first pathway has been studied primarily with model 
particles such as carbon, Au and MnO2 in experimental inha-
lation models in rats (Oberdörster et al 2004; Oberdörster, 
Oberdörster et al 2005). The pathway via the BBB has been the 
topic of research for a while, especially for drug delivery. Studies 
suggest that the physiological barrier may hinder the distribution 
of some proteins and viral particles after trans-vascular delivery 
to the brain, suggesting that the healthy BBB contains defense 
mechanisms protecting it from blood-borne nanoparticle expo-
sure. When nanoparticles with different surface characteristics 
were evaluated, neutral nanoparticles and low concentrations 
of anionic nanoparticles were found to have no effect on the 
BBB, whereas high concentrations of anionic nanoparticles and 
cationic nanoparticles were toxic for the BBB (Nel et al 2006). 
Fullerenes and C60 nanoparticles have been shown to induce 
the production of reactive oxygen species, oxidative stress, and 
rapid brain lipid peroxidation in marine species. Because of all the 
negative effects on the brain by nanoparticles, further tests would 
need to be done before using fullerenes and C60 for human and 
industrial use (Oberdorster 2004).
Conclusion
Although there is a considerable amount of data on the toxicity 
of nanoparticles, this data is mainly based on a small sampling 
and the assumption that a lot of effects by particulate matter 
are driven by the ultrafine particle fraction in it (Oberdörtster, 
Oberdörster et al 2005). This small sampling doesn’t really give 
enough information to adequately determine the potential haz-
ards. Although hazard identification is the general approach for 
safety evaluation of healthcare products, it is recommended to 
add testing driven by the anticipated application and classification 
by risk. Some engineered nanoparticles that are airborne will 
pose inhalation and cardiovascular hazards, while cosmetics with 
nanoparticles provide dermal exposures. Each nanoparticle for-
mulation should be tested on a case-by-case basis in the requisite 
ways focusing on their method of entry. In this respect the poten-
tial adverse effects of empty particles should also be considered. 
In developing testing procedures and protocols a number of basic 
issues need to be considered:
1) It needs to be determined whether noticed effects are caused 
only by nanoparticles, or are the adverse effects caused by some-
thing else and only aggravated by nanoparticles. It is clear from 
research that both PM and ultrafine particles can cause inflam-
mation, cancer, etc., but these new and smaller nanoparticles may 
cause different effects. 
2) Most of the conclusions drawn about nanoparticles are based 
on correlations made between the behavior of ultrafine particles 
and PM’s to that of nanoparticles. The question is how much of 
a correlation is permitted to be drawn, how many assumptions 
can be made, as manufactured nanoparticles and ultrafine/ PM 
particles are not identical.
3) The scientific world is dealing with a increasingly growing num-
ber of nanomaterials. All have the potential to create a new toxic 
effect that has never been studied before. The current testing and 
classification system for nanoparticles does not seem sufficient 
to fully identify and quantify the toxicological effects of these new 
nanoparticles. 
For years pharmaceutical sciences have been using nanoparticles 
to reduce toxicity and the side effects of drugs. Up to recently it 
was not realized that these drug carrier systems themselves may 
cause risks to the patient. The type of hazards that are introduced 
by using nanoparticles for drug delivery are beyond what is posed 
by conventional hazards imposed by chemicals. However, as of 
current data, the scientific example for the possible toxic and ad-
verse reactivity of nanoparticles is lacking and we have little un-
derstanding of the basics of the interaction of nanoparticles with 
living cells, organs and organisms. A conceptual understanding of 
biological responses to nanomaterials is needed in order to de-
velop and apply safe nanomaterials in drug delivery in the future. 
Furthermore, a close partnership between those working in drug 
delivery and those working in particle toxicology is necessary for 
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the exchange of concepts, methods and to establish a common 
system for identifying the potential dangers of nanoparticles. 
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